TARIS Biomedical® is a clinical stage specialty pharmaceutical company focused on developing a pipeline of innovative treatments for bladder diseases. Current therapies for these conditions are characterized by limited efficacy and/or systemic side effects. TARIS Biomedical®’s delivery platform is designed to improve treatment by providing controlled, sustained delivery of drug directly to target tissues. TARIS®’ most advanced product candidate, LiRIS®, is currently in Phase 2 clinical development for the treatment of Interstitial Cystitis. TARIS Biomedical®’s technology was developed by internationally renowned scientists from the Massachusetts Institute of Technology, Robert Langer Sc.D. and Michael Cima Ph.D. and is based in Lexington, MA.
Ed Kania is on the Board of Directors.